By Isabella Hornick
Since its first transplant in March 2022, the Mount Sinai Lung Transplantation Program has performed a total of 35 lung transplants with a 180-day survival rate of 88.6%, according to a presentation. Read the article in Healio.
A new diagnostic method could help identify one of the deadliest types of interstitial lung disease (ILD) sooner, allowing for faster treatment and improved patient outcomes.
Idiopathic pulmonary fibrosis (IPF) is one of the most serious and common types of ILD, occurring most often in patients 60 and older with an average survival time of three to five years. At any given time roughly 300 patients are being treated for IPF in London, Ontario. Globally, it is the number one reason for lung transplants. Read more in Technology Networks.